Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. - Wikidata - awgldk - TriplyDB

Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment.

Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment.

http://www.wikidata.org/entity/Q34579883

about

Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant Canadian hereditary angioedema guideline.Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice.Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain.Hereditary angioedema due to C1 - inhibitor deficiency in Switzerland: clinical characteristics and therapeutic modalities within a cohort study.Hereditary angioedema: epidemiology, management, and role of icatibant In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency.The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks.High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert® (C1-INH) Registry.Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.Management of angioedema without urticaria in the emergency department.Optimizing hereditary angioedema management through tailored treatment approaches.Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey.Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency.Icatibant as acute treatment for hereditary angioedema in adults.A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.Efficacy of on-demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency.Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema.Hereditary Angioedema: The Economics of Treatment of an Orphan Disease.Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus.Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study.Comparison of the Frequency of Angioedema Attack, before and during Pregnancy, in a Patient with Type I Hereditary Angioedema.An analysis of the teaching of intravenous self-administration in patients with hereditary angio-oedema.Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom

P2860

Q29248157-9B372E58-0C43-455B-95A8-CF0B43DEACB8 Q30596332-5766EF1B-1C4D-48DC-9B68-3EBA55655FC3 Q33698175-FCBE5FB1-E9DD-4080-8EBD-FC838738E822 Q35805244-632C8EDA-101C-40CD-9E36-59518D683F8E Q36646147-37E4FDCE-1B49-42D3-8573-053AA7FB06F5 Q36820310-C70D1359-2B44-4290-AF95-F1B71306184D Q36825274-1A5AC313-D51E-49AD-AE50-E2676F5D18B9 Q36960231-8622E7B1-7646-49D7-98D5-0767713D7343 Q36967735-39CFB749-FB75-4FF1-8374-DB0D297BBD90 Q37299151-B1905B05-26E8-4AE1-A1F4-F19296A67184 Q37410712-DB77C82C-2DFF-42D7-B300-EEB7F4A5B7CF Q37690007-B92EDE7C-DC71-4756-B6D7-591504C76D91 Q38314955-C739A9DB-6EC9-4383-9DD9-6080A3A518EB Q38615008-D926AD9D-AC5E-4BD2-8B66-5EF14471A526 Q38687395-954F168D-4135-4A94-B60D-A9CF46B6ACD8 Q38772714-9DC9186A-DE25-4E67-94E2-B026FAF1D9C5 Q38819740-4C097956-B8A8-40BE-A1DE-69ECC3540024 Q38840241-F019D54A-70BC-4FF4-9C4C-BC9926A815A3 Q38859393-B416D6F5-658B-4425-8328-57DE26D0CCD7 Q40611019-C4049618-CC6A-4217-868A-65BD937180C3 Q47903157-1B11224D-E3D1-4508-B45D-0A9761B616ED Q50350621-DF5BA62A-DFE8-421C-92FD-7447B3DE0AD8 Q52624144-B2800708-2E7B-48CE-9992-D8E1D78090E7 Q52806308-2A6476EE-773A-4D57-8139-5218A59DE192 Q52837593-AE5366B4-DF58-4C0B-8941-E44F492622D8 Q52856857-0072A0BF-433C-4480-8F7F-A4E831B517E4 Q58569524-B3797535-A98E-4A88-8368-D8291AB20B2F Q58798864-8CAF6ED5-6A4E-435B-B98C-055E735DE5BC

P2860

Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment.

http://www.wikidata.org/entity/Q34579883

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Hereditary angioedema attacks ...... ter early icatibant treatment.

@ast

Hereditary angioedema attacks ...... ter early icatibant treatment.

@en

Hereditary angioedema attacks ...... ter early icatibant treatment.

@nl

type

label

Hereditary angioedema attacks ...... ter early icatibant treatment.

@ast

Hereditary angioedema attacks ...... ter early icatibant treatment.

@en

Hereditary angioedema attacks ...... ter early icatibant treatment.

@nl

prefLabel

Hereditary angioedema attacks ...... ter early icatibant treatment.

@ast

Hereditary angioedema attacks ...... ter early icatibant treatment.

@en

Hereditary angioedema attacks ...... ter early icatibant treatment.

@nl

P1433

Q34579883-BA1BFB2E-E0FC-4196-9D74-B376A25FB42E

P1476

Q34579883-96302A1E-2B71-40CB-B993-1700D8557AC3

P2093

Q34579883-0F6BBE26-4855-4E93-B53F-69619BEDBF35

Q34579883-120B8294-FA4E-4DA8-A95F-350205096841

Q34579883-23884929-8EEC-41C3-BD58-20B19AFCD563

Q34579883-2B3C3C4B-B3D8-44F9-B7DD-A110A3EF52B0

Q34579883-2ED31082-5659-4F53-A5E7-DF83431AA808

Q34579883-54765AAB-0092-4528-9CAA-60D5863C7C77

Q34579883-659696A9-798E-4049-B925-7D20E4EE940E

Q34579883-66137B28-AD9B-4EA6-967D-8F9D276F7113

Q34579883-950A628B-73FB-4D4F-A77B-5FC749F7FBA2

P2860

Q34579883-21969475-74D9-4DB1-B487-925849BBFD97

Q34579883-275FC7AD-39F5-4F6B-AFB3-A1BF778CB7C7

Q34579883-354078BF-A0A0-4C30-8A1F-9F210F1D43D5

Q34579883-44F4550B-52B8-442E-AFB6-E21B15E364BC

Q34579883-4527BFAB-37A5-445F-9229-0D40ED5F7D01

Q34579883-5565CD72-5301-4E96-ABE0-EAC129FF6D18

Q34579883-57272391-05AC-49C5-96C7-60347196167A

Q34579883-5B2DBA65-3243-407A-8A0B-4115237665BF

Q34579883-65B9445F-D583-4222-AB51-91DDB2FEBBDD

Q34579883-68D998C5-4F1E-4295-8410-C635E444E273

P304

Q34579883-BCE385B7-DE2B-4381-AECB-01D20D025491

P31

Q34579883-EAAE8F4B-5674-4082-A967-C716B93246B9

P356

Q34579883-FEDA682B-C3C1-44DE-93D3-900DC705E6F4

P407

Q34579883-F6C80919-2AF1-4554-AE4D-BC21F84CFFC4

P433

Q34579883-764571EC-BF70-4AD7-9FF5-22D58E624329

P478

Q34579883-FC3E1BDB-F0BC-413F-839E-7B5964A79AAC

P50

Q34579883-9D9A1F32-B6B9-4421-8947-3A2C0431D56A

P577

Q34579883-9CC6B19A-E1A6-4352-AB9B-B45166FBC6BE

P5875

Q34579883-D5AC204E-4080-4D2D-A744-1CBA04B1F506

P698

Q34579883-807658A1-768F-4D74-B427-D77F603FEA89

P932

Q34579883-1E7D0F2A-69E7-464A-9636-B6D9F6D92860

P356

JOURNAL.PONE.0053773

P1433

P1476

Hereditary angioedema attacks ...... ter early icatibant treatment.

@en

P2093

Allen Kaplan

http://www.w3.org/2001/XMLSchema#string

Andrea Zanichelli

http://www.w3.org/2001/XMLSchema#string

Gisèle Kanny

http://www.w3.org/2001/XMLSchema#string

Hilary Longhurst

http://www.w3.org/2001/XMLSchema#string

I O S Investigators

http://www.w3.org/2001/XMLSchema#string

Laurence Bouillet

http://www.w3.org/2001/XMLSchema#string

Marcus Maurer

http://www.w3.org/2001/XMLSchema#string

Vincent Fabien

http://www.w3.org/2001/XMLSchema#string

Werner Aberer

http://www.w3.org/2001/XMLSchema#string

P2860

Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII.

Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group.

Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).

A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

Formation and structure of human Hageman factor fragments.

The bradykinin-forming cascade and its role in hereditary angioedema.

Hereditary angioedema treatment options: the availability of new therapies.

Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.

P304

e53773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0053773

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Teresa Caballero

P577

2013-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235416864

http://www.w3.org/2001/XMLSchema#string

P698

23390491

http://www.w3.org/2001/XMLSchema#string

P932

3563637

http://www.w3.org/2001/XMLSchema#string